HIV

A study from Merck has demonstrated high response to grazoprevir/elbasvir with and without ribavirin across various hepatitis C virus populations, including difficult-to-cure patients.

A trio of studies from AbbVie provides good news for patients with hepatitis C virus, including those with comorbid HIV or cirrhosis.

Women may need more frequent ART doses to prevent HIV transmission than men, a mathematical model suggests

If approved, it would be Gilead's first single-tablet HIV regimen to contain TAF.

Gilead Sciences, Inc., has submitted a new drug application to the FDA for its investigational single-tablet regimen for HIV infection in adult patients.

Following completion of phase 2 trial, phase 3 enrollment expected to start by end of the year.

An investigational HIV drug developed by Merck exhibited a strong overall safety and efficacy profile in a recently completed phase 2b study.

Discovery offers potential target for future HIV treatments.

Could the key to fighting modern illnesses lie in a disease that was an epidemic centuries ago?

Researchers identify mechanisms that trigger hematopoietic stem cell production.

Antiretroviral therapy provides similar benefits for stimulant users and non-users alike.

The vaccine that prevents illness and death from pneumococcal infection also combats severe antibiotic-resistant disease in young children.

Provides use, cost forecast based on testing, future treatment rates.

Harvoni is comprised of sofosbuvir, a previously approved HCV drug marketed under the brand name Sovaldi, and a new drug called ledipasvir.

Tobacco users have an increased risk of oral human papillomavirus type 16, a sexually transmitted virus that is strongly associated with cervical cancer.

Virus was undetectable for 3 years before researchers discovered viral reservoirs have not disappeared.

Parents who know about the human papillomavirus are not more likely to get their adolescent daughters vaccinated.

Findings of study provide new options for future vaccine development.

Investigators aim to reduce side effects of therapy with sofosbuvir in children with hepatitis C.

Gilead has refined the pharmacokinetics of tenofovir disoproxil fumarate (TDF), an anchor drug in several single-tablet medications for HIV-1, to create tenofovir alafenamide (TAF). Phase II results indicate superior renal outcomes and equivalent clinical outcomes with TAF versus TDF.

Among HIV-positive patients, concurrent use of medications is associated with nonadherence to antiretroviral therapy.

An experimental single-tablet regimen for treatment-naïve adults infected with HIV demonstrated non-inferiority to an FDA-approved combination pill in achieving undetectable viral load.

Much higher rate of patients in real world discontinuing high priced treatment than during clinical studies.

Study finds tolerance varies between individuals determined by their genes.

Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.

Data indicates that a simeprevir-based therapy is efficacious in patients with HIV-1/HCV genotype 1 coinfection.

A recent study published in the journal Hepatology indicates that as many as 11% of baby boomers had a positive test result for presence of anti-HCV antibodies.

Study finds HIV suppression reduces hepatitis C viral replication over time.